News Release

Printer Friendly Version View printer-friendly version
<< Back
Cidara Therapeutics Announces Presentation of Data from its Antifungal Drug Development Programs at ECCMID 2016
April 6, 2016 at 7:01 AM EDT

Presentations to Highlight Results from the Phase 1 Study of Novel Echinocandin CD101 IV Demonstrating Excellent Safety and Supporting Once-Weekly Dosing

SAN DIEGO--(BUSINESS WIRE)--Apr. 6, 2016-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that data from preclinical and clinical studies of its novel echinocandin, CD101, will be presented at the 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, April 9-12, 2016. Specifically, Cidara’s presentations will feature results from the successful Phase 1 dose-escalation study of CD101 IV as well as provide an update on the company’s anti-infective product pipeline, including key clinical and regulatory milestones for CD101 and the CloudbreakTM immunotherapy platform.

“Cidara’s presentations at this year’s ECCMID reinforce our commitment to developing novel antifungal therapies to fight serious infections that are becoming increasingly resistant to current standards of care,” said Jeff Stein, Ph.D., president and CEO of Cidara. “Results from our recently completed Phase 1 studies demonstrated that CD101 IV can be safely dosed once weekly at high drug exposures. We expect this to translate to a safe once-weekly treatment for both inpatients and outpatients, especially those with fungal infections that are difficult to treat with existing therapies. We are excited to share data from both of our CD101 programs and our Cloudbreak platform with ECCMID attendees.”

The ECCMID presentations are as follows:

Oral Presentations:

Sunday, April 10: Pipeline Talk (1:00 p.m.2:00 p.m. CET, Pipeline Corner)

  • Cidara Pipeline; T. Sandison

Monday, April 11: Oral Session OS102: Challenges in antifungal treatment (11:30 a.m.12:30 p.m. CET, Hall K)

  • O425: The safety and single-dose pharmacokinetics of CD101 IV: results from a phase 1, dose-escalation study; D. Thye

Poster Presentation:

Tuesday, April 12: Poster Session: Antifungal drug treatment (12:30 p.m.1:30 p.m. CET, Poster Area)

  • P1578: Allometric scaling and the chimpanzee as a surrogate for human pharmacokinetics of CD101, a novel echinocandin; V. Ong

About Cidara Therapeutics

Cidara is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard-of-care therapies. Cidara's initial product portfolio comprises two formulations of the company's novel echinocandin, CD101. CD101 IV is being developed as a once-weekly high exposure therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical is for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. In addition, Cidara has developed a proprietary immunotherapy platform, Cloudbreak™, designed to create compounds that direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effectiveness, safety, long-acting nature, anticipated human dosing and other attributes of CD101 IV and CD101 topical, and their potential to treat infections, as well as the intended design of current and future Cloudbreak compounds. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; changes in Cidara’s plans to develop and commercialize its product candidates; Cidara’s ability to obtain additional financing; Cidara’s ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Cidara’s Form 10-K most recently filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Source: Cidara Therapeutics, Inc.

INVESTOR CONTACT:
Westwicke Partners, LLC
Robert H. Uhl
Managing Director
858-356-5932
robert.uhl@westwicke.com
or
MEDIA CONTACT:
Sam Brown Inc.
Mike Beyer
312-961-2502
mikebeyer@sambrown.com